Bridging Innovation and Access: Randomized, Single-Dose, Open-Label, Parallel-Group Bioequivalence Study of Generic and Innovator Injection Semaglutide in India
Radhakrishna Vaddem
Journal of Social Sciences, Published online: 20 April 2026; doi:10.3844/ajptsp.2026.9.15 Semaglutide, a long-acting Glucagon-Like Peptide-1 (GLP-1) receptor agonist, is effective in improving glycemic control, reducing body weight, and lowering cardiovascular risk in Type 2 Diabetes Melli...